Strategies for colon cancer prevention by Jan Björk
REVIEW ARTICLE
Strategies for colon cancer prevention
Jan Björk
Received: 30 April 2010 /Accepted: 5 August 2010 /Published online: 12 September 2010
# European Association for Predictive, Preventive and Personalised Medicine 2010
Abstract Colorectal cancer (CRC) is common and is
associated with a considerable mortality. Morbidity and
thereby mortality can be reduced by using different
prevention strategies such as lifestyle interventions and
chemoprevention. Endoscopic surveillance of high-risk
individuals and population-based endoscopic screening of
average-risk individuals enables detection and removal of
premalignant lesions (adenomas) as well as presymptomatic
detection of cancer. Implementation of cancer detection
tests such as fecal occult blood tests (FOBTs) is another
strategy to reduce cancer mortality by early detection of
CRC. Personalized management, based on estimates of the
individual risk using information concerning environmental
factors, lifestyle, family history, personality, social back-
ground and phenotype in combination with a variety of
biomarkers such as genotype, will become more important
as a strategy to optimize CRC prevention in the future.
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Introduction
Colorectal cancer (CRC) is one of the most prevalent
malignancies in Western countries with a life-time risk of 5%
to 6% [1]. Global statistics shows that European countries
have a leading position, both in terms of incidence and
mortality of CRC. It has been estimated that approximately
50% die of the disease. The incidence and mortality in CRC
varies over countries even within Europe indicating an
influence of other factors such as lifestyle and screening
practices [2]. CRC could be divided into at least three types:
sporadic, hereditary and colitis-associated. A large body of
evidence indicates that diet and lifestyle, family history and
chronic inflammation are risk factors for CRC. Thus, primary
prevention by modification of environmental factors and
lifestyle, identification, surveillance and prophylactic treatment
of high-risk individuals and the use of chemoprevention are
important. However, the most efficient way to prevent CRC or
death from CRC among the general population is screening
targeting the average risk individuals. Therefore population-
based screening programs, including all people eligible to
attend screening on the basis of age and geographical area of
residence, are currently being implemented in several Euro-
pean countries and more will follow. In the United States there
is a trend towards a decrease in CRC morbidity and mortality.
Microsimulation modeling demonstrates that declines in CRC
death rates are explained to a small but demonstrable extent
by risk factor reductions and improved treatments and to a
great extent by screening [3]. The aim of population-based
screening is to discover latent disease in the average risk
population in order to detect early stages which can be cured
by treatment before it poses a threat to the individual and/or
the community [4]. CRC is particularly suitable for screening
since it is common and believed to develop gradually
according to the adenoma-carcinoma sequence [5]. The
time-span from an early adenoma to an established CRC is
unobserved, but is estimated to take at least 10 years [6], thus
providing an opportunity for early detection and intervention.
Moreover, removal of colorectal adenomas has a preventive
effect on CRC [7] and detection of CRC at an earlier stage
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affects mortality [8] which indicates that interventions along
the adenoma-carcinoma pathway have a positive impact on
outcome. Identification and surveillance of high-risk popula-
tions such as individuals belonging to families with hereditary
CRC syndromes and patients with inflammatory bowel
disease (IBD) are other measures of great importance.
Individuals with a family history of CRC indicating a genetic
predisposition but without detectable genetic markers or
individuals with a phenotypic appearance indicating high-risk
is a third group where surveillance is justified. There are
several screening options for CRC available where fecal
occult blood tests (FOBTs) and lower endoscopy are the most
commonly used.
Primary prevention
Primary prevention strategies are targeted to prevent CRC
in an otherwise healthy population. The decline in CRC
seen in the United States is prognosticated to continue if
risk factor modification remains at current rates. With
favorable trends in risk factor exposure decrease could
probably be even more pronounced. Many cancers have
modifiable risk factors, although risk factor reduction
usually results in long-term, not short-term, improvements
in cancer incidence. Thus, the impact of changing preva-
lence of CRC risk factors must be assessed over a long time
to observe impact [9].
Physical inactivity
Lifestyle such as lack of physical exercise is a risk factor
for CRC [10] and decreased occupational physical activity
increases the risk for colon cancer [11].
Obesity
There is considerable evidence supporting the concept that
both overweight and obesity are associated with an increased
risk of CRC. Obesity also increases the risk of colon
adenomas [12]. Overall, obesity approximately doubles the
relative risk of adenomas. A meta-analysis of six studies
estimated a 3% increase in CRC risk per one unit increase in
body mass index (BMI). Abdominal obesity is a stronger
risk factor than truncal obesity or BMI [13, 14].
Smoking
Smoking is a strong predictor of CRC [15, 16]. A history of
more than 20 pack-years of smoking increases the risk for
colorectal adenomas and CRC [17, 18] and has been shown
to account for 12% of all deaths from CRC [19, 20]. Based
on these data, special efforts may be justified to ensure that
screening takes place in active smokers and in former who
have smoked for more than 20 pack-years.
Diet
The geographic differences in CRC incidence could, at least
to some extent, be attributed to differences in diet habits.
The association of high incidence of CRC with diets
containing large amount of red meat emphasises the impact
of diet [21]. The WCRF [22] recognizes that there is limited
but suggestive evidence that food containing animal fat
increases the risk of CRC. But there is also data suggestive
of a causal relationship between high intake of n-3 long-
chain polyunsaturated fatty acids (LC-PUFA) and reduced
risk of CRC, indicating that fish intake probably have a
CRC protective effect [23]. A systematic review of five
studies failed to show any benefit of increased dietary fiber
intake for reducing incidence or recurrence of adenomatous
polyps [24]. The role of nutritional supplementation is
difficult to assess. Nutritional chemoprevention trials had to
be carried out with large number of patients studied for
long duration, measuring CRC as an end point. Folic acid
has been identified as possible agents for the chemo-
prevention of CRC. However, a recent meta-analysis
showed no such evidence [25]. Pooled data from 60
epidemiological studies on CRC cases showed that higher
consumption of milk/dairy products reduces the risk of
colon cancer, and high calcium intake reduces the risk of
CRC. Evidence from two randomized controlled trials
suggests that calcium supplementation contribute to a
moderate degree to the prevention of colorectal adenomas.
Vitamin D was associated with a non significant reduction in
CRC risk [26]. The Polyp Prevention Study was a clinical
trial of antioxidant vitamins (ß-carotene, vitamins C and E).
No effect was seen on recurrence of colorectal adenomas
compared to placebo [27]. A high-quality meta-analysis of
eight trials found that, compared with no treatment or
placebo, there was no benefit of antioxidants (beta-carotene,
vitamin A, vitamin C, vitamin E, or selenium) in decreasing
the risk of CRC. Vitamin E was, in fact, found to increase
the risk of colorectal adenomas [28].
Chemoprevention
Nonsteroidal anti-inflammatory drugs (NSAIDs)
NSAIDs including selective cyclooxygenase-2 inhibitors
(COXIBs) have a chemopreventive effect on CRC [29].
Elevated cyclooxygenase-2 (COX-2) expression is found in
most CRC tissue and is associated with poor outcome in
terms of survival among CRC patients. NSAIDs exert their
anti-inflammatory and antitumor effects primarily by
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reducing prostaglandin production by inhibition of COX-2
activity [30]. It has been possible to reduce the formation of
colorectal adenomas of both familial and sporadic origin by
treating with NSAIDs [29, 31]. COXIBs have also been
shown to cause regression of polyps in randomized studies
on patients with familial adenomatous polyposis (FAP) [32,
33]. Evidence of long-term efficacy of NSAIDs is,
however, currently lacking and potential severe adverse
events must be taken into account [29]. Moreover, the use of
NSAIDs in FAP patients does not replace prophylactic
colorectal surgery. Currently, the use of NSAIDs is restricted
as adjunctive treatment in FAP patients with ileorectal
anastomosis in order to reduce polyp burden. However,
endoscopic surveillance of the rectum is still advocated [34].
Aminosalicylic acid (ASA)
ASA has in observational studies been associated with
significant reductions in colorectal adenoma recurrence,
CRC incidence, and CRC mortality [35, 36].
5-Aminosalicylate (5-ASA)
Pooled results of observational studies support a protective
association between 5-ASA and CRC or a combined
endpoint of CRC/dysplasia in patients with ulcerative
colitis (UC) [37–39].
Ursodeoxycholic acid (UDCA)
UCDA was one of the earliest agents investigated as a drug
for CRC prevention. In a randomized controlled trial in
patients with colorectal adenomas UDCA significantly
lowered the odds of advanced lesions in men, but not
women [40]. UDCA also has been shown to reduce the risk
of colorectal dysplasia or CRC in patients with primary
sclerosing cholangitis (PSC) and UC [41, 42].
Statins
A population-based case-control study found that CRC was
30% less likely to occur in patients who took statins for at
least 5 years but data from randomized controlled trials are
lacking [43].
Hormon therapy
Two meta-analyses of mostly observational cohort studies
reported a 20–30% reduction in colon cancer incidence in
women who had ever used hormone therapy [44, 45].
However, data from the Women’s Health Initiative study
showed that, although women were at decreased risk of
developing colon cancer, those women who did develop
colon cancer were diagnosed at a more advanced stage than
women who took placebo [46].
Family history
Inherited susceptibility plays an important role in the
pathogenesis of CRC. Thus, it is recommended that a
careful family history always should be obtained. Where a
positive history is presented the empirical risks for the
development of CRC can be determined. When no
hereditary CRC syndrome is evident, screening is based
on empiric risk estimates. For instance, the CRC risk is
increased twofold [47] and the odds ratio is 2.6 for high-
risk adenomas defined as adenomas ≥1 cm in size and/or
villous elements in individuals with only one affected first-
degree relative with CRC which further emphasize the close
relationship between adenomas and CRC and the importance
of the adenoma-carcinoma sequence [48]. The American
College of Gastroenterology (ACG) recommendations are
colonoscopy every 10 years beginning at age 50 years when
following criteria are fulfilled: a single first-degree relative
with CRC or high-risk adenoma, defined as adenoma ≥1 cm
in size, or with high-grade dysplasia or villous elements,
diagnosed at age ≥60 years (Grade 2 B). The recommenda-
tions are colonoscopy every 5 years beginning at age 40, or
10 years younger than age at diagnosis of the youngest
affected relative if the following criteria are fulfilled: single
first-degree relative with CRC or advanced adenoma
diagnosed at age <60 years or two first-degree relatives with
CRC or high-risk adenomas (Grade 2 B) [49].
If phenotype and/or inheritance pattern indicate an
inherited CRC syndrome, genetic counseling, presymto-
matic endoscopic screening and, if appropriate, molecular
genetic testing should be advised. It is possible to test
selected subjects for carriage of germline mutations in
genes responsible for Lynch syndrome/hereditary non-
polyposis colorectal cancer (HNPCC), familial adenoma-
tous polyposis (FAP), Peutz-Jeghers syndrome, and
juvenile polyposis which are all autosomal dominant
hereditary syndromes with CRC predisposition. Molecular
genetic testing is also possible for MUTYH- associated
polyposis (MAP), a syndrome resembling FAP but, unlike
FAP, inhereted in an autosomal recessive fashion. Once the
mutation has been found selected members of the family (at
risk individuals), who are identified from the pedigree, can
be offered genetic testing.
Before genetic testing is performed in patients who meet
the criteria for Lynch syndrome microsatellite instability
testing and / or tumor immunohistochemical staining for
mismatch repair proteins should be performed. Patients with
positive tests can be offered genetic testing and, if the
mutation is found, all family members at risk can be offered
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genetic testing. ACG recommends that patients with positive
genetic testing and those at risk in families where genetic
testing is unsuccessful should be offered colonoscopy every
1 year to 2 years beginning at age 20–25 years, until age
40 years, then annually thereafter (Grade 2 B) [49].
The European guidelines recommend that individuals
with a FAP- phenotype should undergo APC-mutation
testing and, if negative, MUTYH-mutation testing. Patients
with FAP or at risk of FAP should undergo annual flexible
sigmoidoscopy or colonoscopy until preventive surgery is
performed [50]. Despite surgical procedure used post-
surgical endoscopic surveillance is mandatory. Patients
with ileorectal anastomosis, ileal pouch, or an ileostomy,
should undergo endoscopic surveillance approximately
every 6–12 months according to the ACG recommenda-
tions (Grade 2 B). Individuals with less dense polyp burden
(<100 colorectal polyps) should be offered genetic counsel-
ing, consideration of APC- and MUTYH- mutation testing,
and individualized colonoscopy surveillance depending on
the size, number, and pathology of polyps seen according to
the same recommendations (Grade 2 C) [49]. Despite of
phenotype it is not always possible to find the mutation
causing the syndrome. In these families endoscopic
surveillance of at risk individuals is recommended. Screen-
ing strategies targeting risk populations based on family
history of CRC have been estimated to prevent up to 15–
20% of all CRC [51].
Inflammatory bowel disease (IBD)
It was shown decades ago that longstanding extensive
ulcerative colitis (UC) was associated with an increased risk
of CRC [52, 53]. UC-associated CRC are more often
multiple, broadly infiltrating, anaplastic, and uniformly
distributed throughout the colon, and seem to arise from
flat mucosa and not from adenomas in comparison with
noncolitis-associated CRC [54]. After 10 years of extensive
UC, the cancer risk has been reported to increase with 0.5–
1% per year [55]. Even patients with left-sided UC reach
similar levels of cumulative cancer risk but first after 30–
40 years of disease [56]. Regular surveillance colonoscopy
has been proposed after 8–10 years of colitis with multiple
biopsies at regular intervals. The finding of high grade
dysplasia (HGD) in flat mucosa is an indication for
prophylactic colectomy or proctocolectomy. Patients espe-
cially at risk for CRC are those with primary sclerosing
cholangitis (PSC) [57]. It is therefore justified to start
colonoscopic surveillance as soon as the coexisting diag-
noses of UC and PSC are established and offer this
patients treatment with UCDA [42]. In addition, a family
history of CRC is also an independent risk factor [58].
Only indirect evidence indicate that surveillance colono-
scopy is likely to be effective at reducing the risk of death
from UC-associated carcinoma, particularly in those with
long-standing extensive colitis [59]. Pharmacological
intervention with 5-ASA has been shown to reduce the
risk of CRC and dysplasia up to 50% [37]. Previous
epidemiological studies imply that an increased risk of
CRC is valid for Crohn’s disease as well [59, 60].
Screening
Population based CRC screening has been introduced in
several countries throughout the world. The age range for a
screening program should include a cohort of the popula-
tion fulfilling the criteria of both high incidence of CRC
and still a considerable life-expectancy. Colonoscopic
detection of CRC is uncommon in asymptomatic individ-
uals below 50 years of age. The low yield of screening
colonoscopy in younger adults is consistent with current
recommendations, not starting screening before age 50 in
individuals at average risk [61]. CRC screening tests could
be divided into cancer prevention and cancer detection
tests. Cancer prevention tests have the potential to detect
both cancer and adenomas, whereas cancer detection tests
have low sensitivity for adenomas but also lower sensitivity
for cancer compared with that in cancer prevention tests
(imaging tests).
Imaging tests
Endoscopic screening examination could be performed
either as a flexible sigmoidoscopy or as a colonoscopy. In
CRC screening of average-risk individuals both methods
are used. Sigmoidoscopy is easier to perform and less time
consuming and is associated with less complications
compared to colonoscopy [62]. Case-control studies of
sigmoidoscopy, have shown morbidity and mortality
reductions of distal CRC of 80 [63] and 60% [64],
respectively, in screening populations. Overall, flexible
sigmoidoscopy detects 60–70% of the significant lesions
detected by colonoscopy [65]. The Telemark Polyp Study
conducted in Norway was a randomized controlled trial
where flexible sigmoidoscopy was used demonstrated a
significant reduction in the incidence of CRC [66]. A
similar study from the United Kingdom presented data on
the attendance rate which was only 45% [31]. The evidence
that colonoscopy prevents incident CRCs and reduces the
mortality from CRC is indirect but substantial. Notably, no
prospective randomized controlled trial, comparing colono-
scopy with no screening, has been carried out. However,
cohort studies containing patients, who have undergone
colonoscopy and polypectomy have shown a 76–90%
reduction in CRC morbidity compared to reference pop-
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ulations [7, 67]. Case-control studies of colonoscopy have
shown an 80% reduction in the CRC morbidity [68] and a
50% reduction in mortality from CRC [69]. Population-
based studies associated increased use of colonoscopy
with earlier and more favorable stages in CRC presentation,
and with reductions in the incidence of CRC [70, 71]. In a
very recent study no CRCs were detected at colonoscopy in
participants who had a negative colonoscopy an average of
11.9 years previously, compared with the 8.4 CRC cases
expected based on age- and gender-specific prevalences
among participants who had not received a colonoscopy.
The low risk of CRC after a negative colonoscopy support
that screening intervals can be extended to at least 10 years
after a negative index colonoscopy [72]. Major advantages
of colonoscopy are that it allows examination of the entire
colon, as well as single-session diagnosis and treatment.
Disadvantages are the requirement for thorough bowel
preparation and the perforation risk [73, 74]. Most
perforations are related to polypectomy. However, use of
effective polypectomy techniques is critical for adequate
resection of larger polyps. Two studies, addressing this
issue, come to the conclusion that about 25% of incident
cancers occurring after colonoscopy result from ineffective
polypectomy [75, 76]. Several studies have shown that the
detection rates of adenomas differs a lot between different
colonoscopists, including high-risk adenomas [77–79].
Thus, the impact of colonoscopy depends critically on
high-quality baseline examinations. Inadequate bowel prep-
aration is common, and inadequate preparation has been
shown to impair the detection of polyps [80, 81], and has
also been shown recently in prospective colonoscopy
studies to correlate with polyp detection [82–84]. CT
colonography is a viable alternative in patients who decline
colonoscopy. The rational is that the sensitivity for polyps
≥1 cm in size in the most recent multicenter trial was 90%
[85]. The CT colonography probably has a lower risk of
perforation than colonoscopy in most settings, but for several
reasons it is not considered the equivalent of colonoscopy
as a screening strategy. First, the evidence to support an effect
of endoscopic screening on prevention of incident CRC and
mortality is overwhelming compared with that for CT
colonography. Second, the inability to detect polyps ≤5 mm,
which constitutes 80% of colorectal neoplasms, and whose
natural history is still not understood, necessitates perfor-
mance of the test at 5-year, rather than 10-year intervals [86].
Fecal bleeding tests
Guaiac-based fecal occult bleeding test (gFOBT) has so far
been the most frequently used test in screening programs. It
detects the peroxidase reaction of hemoglobin, which
causes the detection paper impregnated with guaiac resin
to turn blue. Diet restrictions are necessary to avoid falls
positive results. There is good evidence that gFOBT
reduces mortality of CRC by 15–33% [87]. There is still
no clear recommendation regarding optimal time interval
since only the interval up to 2 years has been investigated.
The immunochemical FOBT (iFOBT) is more expensive
than the gFOBT but the adherence is better [88, 89]. iFOBT
reacts exclusively to human hemoglobin. Several qualita-
tive and quantitative tests are presently available, with
varying levels of sensitivity and specificity.
New screening methods include tests which examine the
stool for the presence of abnormal DNA are commercially
available. Generally, these tests have higher sensitivity but
lower specificity than gFOBT [90]. Fecal DNA testing is
also more expensive. Additional disadvantages of fecal
DNA testing include no established data on which to
determine an optimal interval, and the lack of clinical
recommendations on how to respond to patients who have
positive DNA tests and negative colonoscopies. Introduc-
tion of organized, population-based, colorectal cancer
screening using FOBT has the potential to reduce overall
CRC cancer mortality. However, a recent study from the
United Kingdom shows that socio-economic variation in
screening participation could exacerbate existing inequal-
ities in mortality. The results showed a strong socio-
economic gradient in FOBT uptake, which declined from
49% in the least deprived quintile of postcodes to 38% in
the middle quintile and 32% in the most deprived quintile.
Variation in socio-economic deprivation between sectors
accounted for 62% of the variance in return rates, with little
attenuation as a result of controlling for ethnic diversity,
household mobility or health status. These results highlight
the need to understand the causes of socio-economic
gradients in screening participation and address barriers
that could otherwise influence outcome in CRC survival
[91]. ACG recommends a preferred cancer prevention test
with colonoscopy every 10 years (Grade 1 B) starting at age
50 years in those without a family history of colorectal
neoplasia and a preferred cancer detection test using annual
iFOBT to detect occult bleeding (Grade 1 B). In clinical
settings, in which economic issues preclude primary
screening with colonoscopy, or for patients who decline
colonoscopy, one of either flexible sigmoidoscopy every
5–10 years or CT colonography every 5 years should be
offered. As cancer detection test, occult blood detection
through the iFOBT is recommended [49].
Surveillance
Colonoscopy is used for early detection and prevention of
CRC by identification of CRC and removal of colorectal
polyps. An autopsy survey and a prospective necropsy
study of the colon and rectum showed that adenomas were
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very common lesions occurring in approximately 50% and
30% of the patients, respectively [92, 93]. Approximately
70% of colonoscopically removed polyps are adenomas
[94]. Adenomas are benign lesions that, by definition,
display dysplasia. It is postulated that almost all CRCs arise
from adenomas but only a small fraction of them undergo
malignant transformation. It is estimated that the develop-
ment from normal mucosa via adenoma to CRC takes
several years [5]. The purpose of surveillance endoscopy is
to detect and resect synchronous adenomas missed during
the initial colonoscopy and to remove metachronous lesions
before they get malignant. Several studies have been
performed investigating the recurrence rate of adenomas
in patient with adenomas at previous colonoscopy. The risk
of metachronous adenomas is high, between 42% and 60%
after 3 years and 4 years, respectively according to two
previous studies [95, 96]. The majority of these lesions are
small and probably of low clinical significance. The
National Polyp Study (NPS) has shown that only 3.3% of
the patients with colorectal adenomas had advanced lesions
including 2 early CRCs 3 years after the index colono-
scopy. Based on this an endoscopic surveillance interval of
at least 3 years was recommended [97]. The miss rate of
synchronous polyps at colonoscopy is not neglectable
[98]. It is however clear that that some individuals are
predisposed to a faster rate of polyp development. Pre-
dictors of adenoma recurrence are number and size of
adenomas. Patients with up to 2 adenomas measuring less
than 1 cm at initial colonoscopy have a low risk of
developing adenomas of clinical importance within 3 years
whereas patients with 3 or more adenomas with at least one
measuring 1 cm or more is a high-risk population which is
recommended follow-up colonoscopy at 3 years [99].
Predictors of colorectal cancer are, except for number and
size, the histological features of tubulovillous or villous
growth [100]. Colonoscopic removal of at least 1 adenoma
larger than 5 mm reduced the risk of subsequent CRC
development compared with that expected in the general
population indicating that endoscopic intervention is effi-
cient in reducing morbidity in CRC in patients under regular
colonoscopic surveillance [101]. Moreover, prevalence of
left-sided advanced colorectal lesions, but not right-sided
advanced lesions, has been shown to be reduced within a
10-year period after colonoscopy, even in the community
setting [102]. Resources in terms of money and accessibility
as well as compliance rate have to be taken into account
when designing the endoscopic surveillance setting.
Outlook
CRC morbidity and mortality can be reduced. A concerted
action including lifestyle changes, chemoprevention, sur-
veillance of high-risk individuals, and population-based
screening of average-risk individuals is at present the most
efficient strategy. Factors that have to be taken into account
are compliance, sensitivity, specificity, cost, and safety.
Insufficient adherence to lifestyle recommendations and
low attendance to screening programs are important factors
that affect the outcome of CRC prevention in the general
population and must by all means be improved. As
predictive diagnostics, such as genetic testing using
advanced molecular technologies, develop and become
more widely used the population of well defined and more
motivated high-risk individuals will increase in size
compared with today. Once a high-risk individual has been
identified targeted preventive measures and treatment can
be implemented. In the future, personalized surveillance
and treatment based on the risk profile involving the
genetic background, a variety of biomarkers, phenotype,
lifestyle, personality and social background probably will
become more important as a strategy to optimize CRC
prevention.
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